We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.71B
AUM Growth
-$646M
Cap. Flow
+$138M
Cap. Flow %
3.73%
Top 10 Hldgs %
52.04%
Holding
130
New
26
Increased
23
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$76.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.9M
3
FOLD
Amicus Therapeutics
FOLD
+$33.6M
4
AMRN
Amarin Corp
AMRN
+$25M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$21.8M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$54.5M
2
ARRY
Array Biopharma Inc
ARRY
+$48.1M
3
BPMC
Blueprint Medicines
BPMC
+$28.5M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$24M
5
QURE icon
uniQure
QURE
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 93.8%
2 Financials 0.46%
3 Consumer Discretionary 0.18%
4 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRCE
76
Grace Therapeutics
GRCE
$33.8M
$3.36M 0.09%
37,081
– –
ONC
77
PUT
BeOne Medicines Ltd
ONC
$34.2B
$2.7M 0.07%
+400,000
New +$53.1M
VCRA
78
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$2.46M 0.07%
99,804
-94,596
-49% -$2.46M
CORV
79
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2M 0.05%
+1,000,000
New +$2.03M
XBI icon
80
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$1.6M 0.04%
900,000
+700,000
+350% +$58.2M
SGEN
81
DELISTED
Seagen Inc. Common Stock
SGEN
$1.45M 0.04%
+17,000
New +$1.25M
EIGR
82
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.43M 0.04%
4,663
– –
AORT icon
83
Artivion
AORT
$1.35B
$1.36M 0.04%
50,000
– –
AXSM icon
84
Axsome Therapeutics
AXSM
$11.9B
$1.09M 0.03%
53,879
– –
SRRA
85
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.04M 0.03%
66,655
– –
MDCO
86
DELISTED
Medicines Co
MDCO
$977K 0.03%
19,532
– –
RACE icon
87
Ferrari
RACE
$68.6B
$955K 0.03%
6,200
– –
ARWR icon
88
Arrowhead Research
ARWR
$12.1B
$866K 0.02%
30,738
-300,000
-91% -$8.88M
BMRN icon
89
PUT
BioMarin Pharmaceuticals
BMRN
$11.9B
$750K 0.02%
+200,000
New +$15.4M
NVCR icon
90
NovoCure
NVCR
$1.79B
$710K 0.02%
+9,489
New +$759K
ZYNE
91
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$635K 0.02%
+200,000
New +$2.25M
MREO
92
Mereo BioPharma
MREO
$51.7M
$534K 0.01%
179,419
– –
MEDP icon
93
Medpace
MEDP
$16.4B
$532K 0.01%
+6,328
New +$478K
KPTI icon
94
Karyopharm Therapeutics
KPTI
$159M
$526K 0.01%
+3,643
New +$494K
ALNA
95
DELISTED
Allena Pharmaceuticals
ALNA
$521K 0.01%
132,300
– –
ALLK
96
DELISTED
Allakos
ALLK
$507K 0.01%
+6,444
New +$425K
NTRA icon
97
Natera
NTRA
$36.5B
$477K 0.01%
14,549
– –
TNDM icon
98
Tandem Diabetes Care
TNDM
$1.26B
$379K 0.01%
6,422
– –
GTHX
99
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$358K 0.01%
+15,702
New +$495K
RARX
100
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$342K 0.01%
+14,455
New +$428K
1 2 3
4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Perceptive Advisors held 130 positions worth $3.71B, down 15% from $4.36B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Perceptive Advisors deployed $138M of net new capital in Q3 2019, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Blueprint Medicines, an estimated $28.5M trimmed.

  • Perceptive Advisors's largest Q3 2019 buy was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $38.9M increase.
  • Perceptive Advisors's biggest Q3 2019 reduction was Blueprint Medicines, cutting an estimated $28.5M.
  • Perceptive Advisors fully exited Ascendis Pharma A/S in Q3 2019, selling an estimated $54.5M.
  • Perceptive Advisors's ten largest holdings make up 52% of its $3.71B portfolio in Q3 2019.
  • Perceptive Advisors opened 26 new positions and closed 21 in Q3 2019.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $3.71B.

Based on Perceptive Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.